XBiotech Inc
NASDAQ:XBIT

Watchlist Manager
XBiotech Inc Logo
XBiotech Inc
NASDAQ:XBIT
Watchlist
Price: 2.43 USD -0.41%
Market Cap: 74.1m USD

XBiotech Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

XBiotech Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
XBiotech Inc
NASDAQ:XBIT
Free Cash Flow
-$24.3m
CAGR 3-Years
-19%
CAGR 5-Years
19%
CAGR 10-Years
3%
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

XBiotech Inc
Glance View

Market Cap
74.1m USD
Industry
Biotechnology

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 97 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. Its True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. The firm has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. The firm is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure.

XBIT Intrinsic Value
Not Available

See Also

What is XBiotech Inc's Free Cash Flow?
Free Cash Flow
-24.3m USD

Based on the financial report for Sep 30, 2025, XBiotech Inc's Free Cash Flow amounts to -24.3m USD.

What is XBiotech Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
3%

Over the last year, the Free Cash Flow growth was 16%. The average annual Free Cash Flow growth rates for XBiotech Inc have been -19% over the past three years , 19% over the past five years , and 3% over the past ten years .

Back to Top